Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 87Lymphoma, Non-Hodgkin 21Leukemia 18Lymphoma, Follicular 17Lymphoma, B-Cell, Marginal Zone 14Lymphoma 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Mantle-Cell 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma, B-Cell 10Recurrence 7Leukemia, Myeloid, Acute 7Hodgkin Disease 7Waldenstrom Macroglobulinemia 6Leukemia, B-Cell 6Hematologic Neoplasms 6Burkitt Lymphoma 6Myelodysplastic Syndromes 5Multiple Myeloma 5Sezary Syndrome 4Mycosis Fungoides 4Leukemia, Hairy Cell 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Myeloproliferative Disorders 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3

Interventions

blinatumomab 15Cyclophosphamide 15Cytarabine 14Azacitidine 11venetoclax 10fludarabine 10fludarabine phosphate 7Methotrexate 7Daunorubicin 7Rituximab 6Vincristine 5Mercaptopurine 5Whole-Body Irradiation 4Melphalan 4Idarubicin 4Etoposide 4Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Dexamethasone 3Cladribine 3Busulfan 3Asparaginase 3thymoglobulin 2pembrolizumab 2pegaspargase 2nilotinib 2midostaurin 2daratumumab 2Vindesine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm, Residual × Bendamustine Hydrochloride × Other hematologic neoplasm × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

NCT03524235 2024-11-12

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Cedars-Sinai Medical Center

Phase 1 Completed
20 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡